Arguing that targeted radionuclide therapeutics (TRTs) allows for the selective delivery of therapeutic radiation doses to tumors, while at the same time reducing non-target toxicities, AdductNE LLC is structured around addressing approaches selectively to increase the tumor residualization of receptor-targeted constructs using protease inhibitors. The firm's proprietary tumor-residualizing TRTs selectively localize in the tumors and form irreversible, high-molecular-weight adducts. Principalsof the firm have demonstrated that utilization of irreversible, protease inhibitors greatly increase the tumor-residualization of two TRT platforms the firm is currently exploring for clinical translation.
